Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALGS

ALGS - Aligos Therapeutics Inc Stock Price, Fair Value and News

0.95USD0.00 (0.00%)Market Closed
Watchlist

Market Summary

USD0.950.00
Market Closed
0.00%

ALGS Stock Price

View Fullscreen

ALGS RSI Chart

ALGS Valuation

Market Cap

41.3M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

3.29

EV/EBITDA

0.37

Price/Free Cashflow

-0.57

ALGS Price/Sales (Trailing)

ALGS Profitability

EBT Margin

-642.89%

Return on Equity

-148.98%

Return on Assets

-95.13%

Free Cashflow Yield

-176.93%

ALGS Fundamentals

ALGS Revenue

Revenue (TTM)

12.6M

Rev. Growth (Yr)

-47.54%

Rev. Growth (Qtr)

-49.84%

ALGS Earnings

Earnings (TTM)

-81.7M

Earnings Growth (Yr)

3.11%

Earnings Growth (Qtr)

3.99%

Breaking Down ALGS Revenue

Last 7 days

-5.8%

Last 30 days

-12.2%

Last 90 days

-5.8%

Trailing 12 Months

-57.2%

How does ALGS drawdown profile look like?

ALGS Financial Health

Current Ratio

3.32

ALGS Investor Care

Shares Dilution (1Y)

2.00%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202313.9M14.5M12.6M0
20226.0M8.2M10.7M13.9M
20210004.4M

Tracking the Latest Insider Buys and Sells of Aligos Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 25, 2023
nuechterlein carole
bought
6,004,150
0.7568
7,933,600
-
Oct 25, 2023
scopa james paul
acquired
138,557
0.7568
183,083
-
Oct 25, 2023
blatt lawrence
acquired
461,858
0.7568
610,277
chief executive officer
Jun 11, 2021
woiwode thomas
acquired
-
-
18,102
-
Jun 11, 2021
woiwode thomas
acquired
-
-
2,226
-
Apr 26, 2021
woiwode thomas
acquired
-
-
18,105
-
Apr 26, 2021
woiwode thomas
acquired
-
-
2,226
-
Oct 20, 2020
woiwode thomas
bought
3,000,000
15.00
200,000
-
Oct 20, 2020
symons julian a.
acquired
-
-
18,517
see remarks
Oct 20, 2020
beigelman leonid
acquired
-
-
254,702
president

1–10 of 24

Which funds bought or sold ALGS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
BAKER BROS. ADVISORS LP
unchanged
-
-172,341
1,378,730
0.02%
Feb 14, 2024
Royal Bank of Canada
reduced
-99.93
-481,000
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
0.1
-83,195
671,736
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
-7,636
61,088
-%
Feb 14, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
sold off
-100
-913,789
-
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
reduced
-18.76
-4,758
12,366
-%
Feb 14, 2024
HarbourVest Partners LLC
unchanged
-
-1,559
12,472
-%

1–10 of 47

Are Funds Buying or Selling ALGS?

Are funds buying ALGS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALGS
No. of Funds

Unveiling Aligos Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
hhlr advisors, ltd.
8.2%
5,971,426
SC 13G/A
Feb 14, 2024
armistice capital, llc
9.99%
7,214,823
SC 13G
Feb 14, 2024
ecor1 capital, llc
9.99%
7,264,147
SC 13G/A
Feb 14, 2024
alyeska investment group, l.p.
9.99%
7,176,767
SC 13G
Feb 14, 2024
baker bros. advisors lp
4.99%
3,664,013
SC 13G/A
Feb 14, 2024
tang capital partners lp
3.0%
2,189,847
SC 13G/A
Feb 08, 2024
versant venture capital vi, l.p.
1.9%
1,457,937
SC 13D/A
Nov 07, 2023
roche finance ltd
15.35%
11,025,941
SC 13G/A
Nov 06, 2023
blatt lawrence
5.3%
3,888,253
SC 13D
Nov 02, 2023
deep track capital, lp
9.99%
7,295,967
SC 13G

Recent SEC filings of Aligos Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 08, 2024
SC 13D/A
13D - Major Acquisition
Jan 30, 2024
SC TO-I
SC TO-I
Jan 25, 2024
SC TO-C
SC TO-C
Jan 25, 2024
8-K
Current Report

Peers (Alternatives to Aligos Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
3.9B
631.9M
-12.60% 32.37%
-26.2
6.17
23.54% 31.53%
SMALL-CAP
1.6B
348.4M
-3.38% -9.50%
25.02
4.46
81.69% -7.29%
521.5M
1.0B
-9.17% -57.89%
-0.95
0.5
-43.15% 58.48%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aligos Therapeutics Inc News

Latest updates
Simply Wall St23 Feb 202410:17 am
Yahoo Finance3 months ago

Aligos Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue-49.8%2,154,0004,294,0002,583,0003,537,0004,106,0003,693,0002,571,000367,0001,537,0001,545,000910,000
Operating Expenses-14.3%22,310,00026,027,00026,641,00026,219,00023,054,00024,086,00038,128,00038,315,00034,605,00031,110,00028,650,000
  S&GA Expenses-30.3%6,443,0009,246,0008,506,0007,119,0005,263,0007,576,0006,452,0009,717,0006,473,0006,556,0005,781,000
  R&D Expenses-5.4%15,867,00016,781,00018,135,00019,100,00017,791,00016,510,00031,676,00028,598,00028,132,00024,554,00022,869,000
EBITDA Margin-14.9%-6.30-5.48-5.84-6.73-10.19-15.11-22.11-28.71---
Income Taxes-96.2%29,000757,00039,00049,000-43,00047,00053,000-57,000126,00028,00045,000
Earnings Before Taxes0.1%-18,012,000-18,034,000-22,916,000-21,837,000-18,664,000-19,877,000-35,562,000-37,772,000-32,998,000-29,790,000-27,629,000
EBT Margin-14.6%-6.43-5.61-5.98-6.90-10.42-15.45-22.61-29.41---
Net Income4.0%-18,041,000-18,791,000-22,955,000-21,886,000-18,621,000-19,924,000-35,615,000-37,715,000-33,124,000-29,818,000-27,674,000
Net Income Margin-14.7%-6.50-5.66-5.99-6.91-10.42-15.47-22.64-29.44---
Free Cashflow-49.3%-20,336,000-13,623,000-22,394,000-16,874,000-17,140,000-25,369,000-20,949,000-37,816,000-25,465,000-23,170,000-30,103,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-19.1%86.0010612214716418321023526321223526592.00110128147
  Current Assets-20.8%75.0094.0010913415016819520424919722025074.00--120
    Cash Equivalents-22.5%70.0091.0079.0081.0086.0071.0010518724018820022132.0023.0025.0070.00
  Net PPE-7.7%4.004.004.005.005.006.006.006.006.007.008.008.009.00--9.00
Liabilities-15.0%31.0036.0037.0043.0042.0046.0058.0051.0046.0043.0039.0045.0046.0041.0035.0029.00
  Current Liabilities-17.5%22.0027.0028.0033.0031.0032.0041.0039.0035.0030.0025.0030.0020.00--14.00
Shareholder's Equity-21.3%55.0070.0085.001041221371531852171691952204.002.002.001.00
  Retained Earnings-4.1%-458-440-422-399-377-358-338-303-265-232-202-174-140---66.20
  Additional Paid-In Capital0.6%5135105065034994964914874834013983954.00--1.00
Shares Outstanding0%44.0044.0043.0043.0043.0043.0043.0043.0042.0038.0037.0038.003.003.003.004.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations-49.4%-20,336-13,616-22,387-16,783-17,137-25,035-20,434-37,480-25,368-23,018-29,796-19,684-16,566-17,694-20,319--
  Share Based Compensation0.4%3,2093,1963,6643,4163,4914,0003,7863,6513,6013,4492,7561,3011,01652.00606--
Cashflow From Investing-100.0%-9.0025,00419,99311,60432,483-9,976-60,404-16,479-40.009,8489,69314,93726,65614,931-23,769--
Cashflow From Financing-105.1%-21.00414-1.00121-19.0083.00-21.0055277,95295.0078.00193,318-94927.00-48.00--

ALGS Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue from collaborations$ 2,154$ 4,106$ 7,329$ 10,370
Revenue from customers1,08505,5190
Operating expenses:    
Research and development15,86717,79150,78365,977
General and administrative6,4435,26324,19519,291
Total operating expenses22,31023,05474,97885,268
Loss from operations(19,071)(18,948)(62,130)(74,898)
Interest and other income, net1,0592843,168795
Loss before income tax expense(18,012)(18,664)(58,962)(74,103)
Income tax benefit (expense)(29)43(825)(57)
Net loss(18,041)(18,621)(59,787)(74,160)
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale securities010996(293)
Other comprehensive income (loss)010996(293)
Comprehensive loss$ (18,041)$ (18,512)$ (59,691)$ (74,453)
Net loss per share, basic$ (0.41)$ (0.44)$ (1.38)$ (1.74)
Net loss per share, diluted$ (0.41)$ (0.44)$ (1.38)$ (1.74)
Weighted average shares of common stock, basic43,496,97542,761,92843,209,65642,647,732
Weighted average shares of common stock, diluted43,496,97542,761,92843,209,65642,647,732

ALGS Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 70,429$ 81,347
Restricted cash74115
Short-term investments 44,480
Other current assets4,1407,603
Total current assets74,643133,545
Operating lease right-of-use assets6,9407,698
Property and equipment, net3,6464,816
Other assets623634
Total assets85,852146,693
Current liabilities:  
Accounts payable2,9414,737
Accrued liabilities12,32216,039
Operating lease liabilities, current3,1973,035
Finance lease liabilities, current58108
Deferred revenue from customers, current1,857467
Deferred revenue from collaborations, current2,0938,743
Total current liabilities22,46833,129
Operating lease liabilities, net of current portion8,3299,201
Finance lease liabilities, net of current portion188230
Deferred revenue from customers, net of current portion 233
Long term liability46 
Total liabilities31,03142,793
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2023 (unaudited) and December 31, 2022, respectively; no shares issued and outstanding as of September 30, 2023 (unaudited) and December 31, 2022, respectively.
Common stock, $0.0001 par value; 320,000,000 shares authorized as of September 30, 2023 (unaudited) and December 31, 2022, respectively; 43,502,582 and 42,922,980 shares issued and outstanding as of September 30, 2023 (unaudited) and December 31, 2022, respectively.44
Additional paid-in capital513,225502,613
Accumulated deficit(458,905)(399,118)
Accumulated other comprehensive income497401
Total stockholders’ equity54,821103,900
Total liabilities and stockholders’ equity$ 85,852$ 146,693
ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.aligos.com
 EMPLOYEES68

Aligos Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aligos Therapeutics Inc? What does ALGS stand for in stocks?

ALGS is the stock ticker symbol of Aligos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aligos Therapeutics Inc (ALGS)?

As of Tue Feb 27 2024, market cap of Aligos Therapeutics Inc is 41.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALGS stock?

You can check ALGS's fair value in chart for subscribers.

What is the fair value of ALGS stock?

You can check ALGS's fair value in chart for subscribers. The fair value of Aligos Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aligos Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALGS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aligos Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALGS is over valued or under valued. Whether Aligos Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aligos Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALGS.

What is Aligos Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 27 2024, ALGS's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 3.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALGS PE ratio will change depending on the future growth rate expectations of investors.